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that patient QoL is maintained following the introduction of
cetuximab plus irinotecan over 12 weeks. However, we must be
mindful of the population of patients assessed/ followed up, the
lack of comparator information and the issues of open label
studies.
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OBJECTIVES: The purpose of this study was to assign utilities to
the three different severity grades of hand-foot-syndrome (HFS)
which is a dose and therapy limiting toxicity in cancer patients
undergoing treatment with e.g. capecitabine, docetaxel, sunitinib
and sorafenib. HFS can develop from mild skin reactions at
hands and feet (grade 1) to major skin reactions with bleeding,
ulceration and severe pain (grade 3). METHODS: In a survey
conducted in a German community pharmacy, randomly chosen
subjects were introduced to the symptoms of HFS using cards
explaining the different HFS grades by pictures of hands and feet,
a clinical deﬁnition and citations of patients. Participants were
asked to imagine suffering from each HFS grade for the next 10
years followed by death. Then they valuated the different grades
using the time-trade-off-method (TTO) and the visual analogue
scale (VAS). RESULTS: Fifty-three participants (30 female =
56.6%, 23 male = 43.4%) valuated the different HFS grades.
Their mean age was 50.8 years (median: 49.0, SD: 18.5, range:
18–86 years). The following mean utilities were assessed using
the TTO: grade 1 = 0.97 (median: 1.00, SD: 0.08), grade
2 = 0.72 (median: 0.80, SD: 0.23) and grade 3 = 0.34 (median:
0.30, SD: 0.22). The VAS resulted in the following mean utilities:
grade 1 = 0.70 (median: 0.70, SD 0.14), grade 2 = 0.37 (median:
0.40, SD: 0.13) and grade 3 = 0.09 (median: 0.10, SD: 0.08). All
differences among the severity grades were statistically signiﬁcant
(p < 0.001). CONCLUSION: The adults questioned see a signiﬁ-
cant impact of the adverse drug reaction HFS on the health status
of patients. Therefore HFS deserves awareness and respect by
health care professionals and requires a high level of patient
information. Furthermore scientists should be encouraged to
conduct more studies concerning prevention and management
of HFS.
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OBJECTIVES: The EQ-5D visual analog scale (VAS) is a patient-
reported rating of overall health that is often reported in clinical
studies. However, few studies are available to guide in the inter-
pretation of meaningful differences in VAS scores. The objective
of this study was to estimate meaningful differences in EQ-5D
VAS scores in cancer, particularly in lung cancer. METHODS:
Secondary data analysis was conducted on a cross sectional study
of 534 cancer patients, including 50 lung cancer patients, who
completed EQ-5D VAS (scaled from 0 (worst imaginable health)
to 100 (best imaginable health)). Anchor-based and distribution
based approaches were used to estimate important differences for
VAS scores. Cancer patients were grouped into clinically mean-
ingful categories anchored by: 1) Eastern Cooperative Oncology
Group performance status (PS), and 2) FACT-G total score-based
quintiles. These anchors were conservative partitions likely to
exceed the true minimum important difference (MID).
Distribution-based criteria applied to each subgroup included 1/2
standard deviation (SD) and the standard error of the measure
(SEM). RESULTS: Estimates of MID for VAS scores based on PS
categories ranged from 8 (average mean difference across catego-
ries) to 11 (SEM) for all cancer patients, and from 8 (0.5 SD) to
12 (average mean difference across PS categories) for lung cancer
patients. Using FACT-G score quintiles, MIDs were the same for
both the overall cancer groups and the lung cancer subgroup
where the average mean difference between quintiles was 7, SEM
was 10 and 1/2 SD was 9. CONCLUSION: The range of esti-
mates representing important differences in EQ-5D VAS scores
was similar between all cancers and lung cancer (7 to 12), with
the lower bounds of MID estimates closer to minimal important
differences, i.e. 7–8. These estimates can help to inform interpre-
tation of EQ-5D VAS scores, particularly in studies of cancer.
PCN68
SENSITIVITYTO CHANGE OFTHE PERFORM
QUESTIONNAIRE (PQ) IN CANCER PATIENTS REPORTING
IMPROVEMENT OR DETERIORATION OFTHEIR
CANCER-RELATED FATIGUE
Baro E1, Cassinello J2, Carulla J3,ValentínV4, Rodríguez C5, Gascón P6,
García-Mata J7, Colomer R8, Gasquet JA9, Perform group G10
13D Health Research, Barcelona, Spain, 2Hospital Universitario de
Guadalajara, Guadalajara, Spain, 3Hospital Verge del Toro, Menorca,
Spain, 4Hospital 12 de octubre, Madrid, Spain, 5Hospital Clínico
Universitario de Salamanca, Salamanca, Spain, 6Hospital Clínic i
Provincial de Barcelona, Barcelona, Spain, 7Hospital Santa Maria Nai,
Orense, Spain, 8Centro Oncológico MD Anderson, Madrid, Spain,
9AMGEN S.A, Barcelona, Spain, 10The PERFORM Study Group,
Barcelona, Spain
OBJECTIVES: Cancer-related fatigue (CRF) is a frequently
reported complaint in cancer patients and survivors. The Perform
Questionnaire (PQ) is a recently validated scale to assess percep-
tions and beliefs about CRF. This study aims to determine how
sensitive to change is the PQ as well as to compare it with the
sensitivity of the FACT-F. METHODS: An observational and
longitudinal multi-centre study was carried out on a sample of
cancer patients with a moderate level of CRF. PQ and FACT-F
were administered at inclusion and 3 months later, as well as
sociodemographics and key clinical indicators. Patient improve-
ment or worsening related to CRF was assessed by means of a
health status item (HSI) self-administered at the second visit on a
Likert-type ordinal scale with 13 response options. RESULTS:
Baseline patient characteristics (n = 437) were: 60.5% women,
mean age 59.1 years, an average of 2.21 years since diagnosis,
33.6% breast cancer, 54.7% with metastasis, Karnofsky mean
score 80.9, and 29.1% with anaemia. Of the 350 patients who
assessed their change with HSI: 208 (59.4%) reported improve-
ment (‘slightly’ to ‘greatly’), 84 (24%) reported worsening
(‘slightly’ to ‘greatly’), and 58 (16.6%) reported no signiﬁcant
change. The overall PQ score showed a better sensitivity to
clinical deterioration (effect 1.04) than to the improvement
(effect size = 0.57), similar to the magnitude of the effect sizes
obtained with FACT-F (0.91 for deterioration; 0.53 for improve-
ment). The effect sizes of PQ dimensions were also higher for the
patients reporting worsening (ranging from 0.92 to 1.06) than
for those reporting improvements (0.51 to 0.59). CONCLU-
SION: The score of PQ has demonstrated a good level of sensi-
tivity both in patients reporting improvement and in patients
reporting deterioration of health status, in a similar magnitude
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than FACT-F. PQ could be helpful in monitoring cancer patients
from clinical research or practice.
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OBJECTIVES: To evaluate patient-reported impairment in
health states from the EuroQol (EQ-5D) assessment and derive
UK preference-weighted utilities during periods of disease pro-
gression (PROG), toxicity (TOX), and time without symptoms
of progression or toxicity (TWiST), based on a recent phase
3, randomized, outpatient study of ﬁrst-line treatment of
poor-prognosis patients with advanced renal cell carcinoma
(RCC) randomized to temsirolimus, interferon, or interferon+
temsirolimus. METHODS: In the clinical study, the EQ-5D was
assessed at baseline, week 12, and week 32, at each grade 3 or 4
adverse event (AE), at study discontinuation, and at study end.
Assessments were classiﬁed by their timing into 3 distinct
periods: TOX (during grade 3 or 4 AEs or AE-related study
discontinuation), PROG (during progression/relapse), and
TWiST (during neither progression nor toxicity). Published
UK-population preference weights were applied to patient-
reported impairments on the EQ-5D domains—mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression—to derive utility values, consistent with EQ-5D
methodology (euroqol.org). Median utility scores were com-
pared across the periods of TOX, PROG, and TWiST. The pro-
portion of patients reporting at least one EQ-5D domain at the
highest level of severity was compared across the 3 periods, using
the chi-square test. RESULTS: EQ-5D response rates were 87%
(260/300) during PROG, 40% (230/570) during TOX, and 99%
(278/279) during TWiST. Median utility values were 0.585 and
0.587 during TOX and PROG respectively, compared with 0.689
for the TWiST period (p < 0.0001). The proportion of patients
with at least one of the EQ-5D domains at the highest level of
severity was 34.2% (89/260) during PROG, 38.3% (88/230)
during TOX, and 18.7% (52/278) during TWiST (p < 0.0001).
CONCLUSION: Patients with advanced RCC reported similar
impairment of EQ-5D domains during periods of toxicity and
progression, signiﬁcantly greater than in the absence of both;
translating to corresponding differences in UK preference-
weighted utility levels.
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OBJECTIVES: To estimate utility weights associated with CML-
related health states among layperson respondents in three coun-
tries. METHODS: We elicited interviewer-administered time
trade-off utilities with a 10-year time horizon for seven CML-
related health states, from convenience samples of laypersons in
Australia (n = 79), the UK (n = 100), and Canada (n = 103).
Standardized health state descriptions were derived in consulta-
tion with a panel of oncologists. Interviewers underwent training
and used a single script. Mean utilities with 95% conﬁdence
intervals (CI) were calculated for each health state. A generalized
linear model was used to determine whether utilities, adjusted for
age and sex, differed by country. RESULTS: The mean age of the
combined sample was 46 years and 46% of respondents were
men. Mean (95% conﬁdence interval) utilities among Australian
respondents were: 0.85 (0.81–0.89) for chronic responders (CR),
0.68 (0.63–0.72) for chronic non-responders (CNR), 0.71 (0.67–
0.76) for accelerated responders (AR), 0.40 (0.34–0.45) for
accelerated non-responders (ANR), 0.44 (0.38–0.49) for blast
responders (BR), 0.12 (0.09–0.15) for blast non-responders
(BNR), and 0.52 (0.45–0.59) for adverse events (AE). Utilities
from UK respondents were: 0.90 (0.87–0.93; CR), 0.72 (0.67–
0.77; CNR), 0.77 (0.73–0.82; AR), 0.53 (0.48–0.57; ANR), 0.55
(0.51–0.60; BR), 0.29 (0.24–0.34; BNR), and 0.52 (0.46–0.57;
AE). Utilities from Canadian respondents were: 0.72 (0.66–0.77;
CR), 0.56 (0.51–0.62; CNR), 0.58 (0.52–0.63; AR), 0.44 (0.39–
0.49; ANR), 0.38 (0.34–0.43; BR), 0.26 (0.22–0.30; BNR), and
0.34 (0.28–0.39; AE). Signiﬁcant differences were observed
between and among countries. CONCLUSION: These data dem-
onstrate the deteriorating impact on quality of life assigned to
disease states occurring through progression of CML. This is one
of the ﬁrst studies to identify systematic differences between
countries in utility weight estimates for oncological health states.
This observation adds to evidence from other disease areas that
systematic differences exist in utilities between countries.
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OBJECTIVES: To know which attributes related to treatment
administration are valued highly in patients with lung cancer
through the conjoint analysis. METHODS: A literature review
was carried out to identify the attributes related to treat-
ment. There were 6 attributes:1-Time spent in the hospital for
treatment administration. 2-Immediate toxicity. 3-Symptoms’
control. 4-Conﬁdence with the physician. 5-Survival. 6-
Treatment administration. Taking into account these attributes
we elaborated 16 hypothetic scenarios. Through interviews with
2nd line lung cancer patients we asked them to order by preferred
scenario. RESULTS: 24 patients were interviewed, with a mean
(SD) age of 60.8 (11.6) years. 58.3% were men. The mean range
by priority order, that is to say, of priority 1 (maximum prefer-
ence) to priority 16 (minimum preference), we observed that the
chosen scenarios in the ﬁrst place were N (No time spent in the
hospital/No immediate toxicity/Moderate symptom control/
Quite a lot of conﬁdence with the physician/More than 6 months
survival/Oral administration) and H (Spending 2 hours per day
during one week in the hospital/No immediate toxicity/Total
control of symptoms/Total conﬁdence with the physician/Less
than 3 months of survival/Oral administration), whereas the ones
less preferred were M (Spending 2 hours per day during one week
in the hospital/No immediate toxicity/No symptom control/Any
conﬁdence with the physician/From 3–6 month survival/
Intravenous administration) and J (No time spent in the hospital/
High immediate toxicity/No symptom control/Any conﬁdence
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